|
Medical network - on July 26, recently, the ministry of human resources and social security issued "about 36 kinds of drugs should be brought into the national basic medical insurance, inductrial injury insurance and maternity insurance drug catalogue b range of notice, will 36 kinds of drugs into the national basic medical insurance, inductrial injury insurance and maternity insurance drug catalogue (2017 edition)", to pay for health care and synchronized to determine the drug standard.
It has long been a catalogue of the healthcare industry. As early as November 2015, the national health and family planning commission officially launched the pilot of national drug price negotiations, and five drugs involving three diseases were included in the negotiations. In February, the new health care catalog was released. After negotiations with related enterprises, 36 of them negotiated successfully.
People club department said Mr. Xu, deputy director of the social security center selected drugs, half for tumor targeted drugs, such as the common tumor such as lung cancer, gastric cancer, disease of heart head blood-vessel, are also included in this eye, diabetes and other major diseases and medical treatment. Compared with the average retail price of 2016, after talks fell to 44% on average, the highest was 70%, and the pay most of the drugs standard is lower than the surrounding international market prices, greatly reduced the medical burden of patients in our country.
Mr. Xu said that the access to the health care drug catalog is a common practice in the world, and there are some early explorations. The 36 drugs that were successfully negotiated included 31 western medicines and five herbal medicines. 15 of the 31 western medicines are tumor therapeutic drugs, which involve common cancers such as lung cancer, stomach cancer, breast cancer, colorectal cancer, lymphoma, myeloma, etc. Other drugs are nephropathy, ophthalmology, psychosis, anti-infection, diabetes and rare diseases. This includes the previous participation of the staff members to reflect the comparison of the multiple rebezumab, trastuzumab, rituximab, boron zolamide, and the amine.
The Chinese medical association branch of ophthalmology ophthalmology group leader Xu Xun, said professor the health talks, countries will ophthalmic drugs for the treatment of macular degeneration (wAMD) licensed included, to many ophthalmologist colleagues and patients are encouraged. From the introduction of rezhuan to China, and the introduction of innovation access mechanism, it is undoubtedly the positive response of the country to many patients' demands. This will help more patients benefit from the treatment of innovative drugs.
Mr. Xu said, through negotiations will have strong social targeted medicine major diseases such as cancer treatment in medicine directory, greatly improve the security level of the basic medical insurance, but also take into account the fund burden ability, and is helpful to guide the reasonable medical behavior, promote the development of medicine industry innovation, health care, business has been basically achieved, ginseng protect people "win-win-win" goals. Next, the department will guide the local governments to implement the implementation of the drug negotiations, so that the masses of the people will get real benefits. |
